PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer

K. Muro, H. Uetake, K. Tsuchihara, K. Shitara, K. Yamazaki, M. Ota, E. Oki, T. Sato, T. Naitoh, Y. Komatsu, T. Kato, K. Yamanaka, I. Mori, J. Soeda, M. Hihara, T. Yamanaka, K. Akagi, A. Ochiai, T. Yoshino

研究成果: Article

元の言語English
ページ(範囲)iv10
ジャーナルAnnals of oncology : official journal of the European Society for Medical Oncology
30
DOI
出版物ステータスPublished - 2019 7 1

ASJC Scopus subject areas

  • Hematology
  • Oncology

これを引用

Muro, K., Uetake, H., Tsuchihara, K., Shitara, K., Yamazaki, K., Ota, M., Oki, E., Sato, T., Naitoh, T., Komatsu, Y., Kato, T., Yamanaka, K., Mori, I., Soeda, J., Hihara, M., Yamanaka, T., Akagi, K., Ochiai, A., & Yoshino, T. (2019). PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 30, iv10. https://doi.org/10.1093/annonc/mdz155.033